Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35

Benzinga Newsdesk www.benzinga.com Negative 91.9%

Neg 91.9% Neu 0% Pos 0%

Roth Capital analyst Boobalan Pachaiyappan downgrades LB Pharmaceuticals (NASDAQ:LBRX) from Buy to Neutral and lowers the price target from $37 to $35.